tions highlighted that response-shift effects may be a result of the instruments used. Individualized (generic) QoL -instruments can be prone to response-shift effects due to their conceptualization addressing a broad range of life aspects. In contrast, diseasespecific PRO measures focusing on specific aspects of disease are less affected by response-shift phenomena.
long-term treatment. ATPIII further notes that adherence appears to be unrelated to sex, age, ethnicity, or socioeconomics. Given that women and racial minorities are less likely to achieve ATPIII lipid goals, we sought to retrospectively examine the relationship between specific demographics and the likelihood of discontinuing antilipidemic medications. METHODS: Retrospective claims analysis of Florida Medicaid adults (age Ն18 years) who initiated antilipidemics during 1997-2006, and who had Ն1 year of data prior to, and Ն3 years of data following, their first antilipidemic claim. Premature discontinuation was defined as no antilipidemic claim for at least 6 months during the Ն3 year follow-up. Chisquare examined categorical variables and Cox proportional hazard examined demographic (sex, age, race/ethnicity) predictors of discontinuation. RESULTS: Of 75,726 patients initiating antilipidemics, most (68.8%; n = 52,085) were female and age Ն50 years (75.7%; n = 57,333); 42.7%, (N = 32,350) were White, 18.5% (n = 14,015) Black, 9.5% (n = 7,163) Hispanic, and 29.3% (n = 22,198) other races/ethnicities. Hispanics were 45%, other races/ethnicities 30%, and Blacks 7% more likely to discontinue treatment (all p < 0.0001) than Whites. Younger patients (<50 years) were 18% more likely to discontinue treatment than older (>70 years) patients (p < 0.0001), and females were 8% more likely to discontinue treatment than males (p < 0.0001). CONCLUSION: Compared to ATPIII, which reports that antilipidemic persistence is unrelated to demographics, we found antilipidemic persistence to be significantly associated with patient sex, age, and race/ethnicity. However, our results are consistent with those of other recent retrospective studies that report a significant relationship between demographics and adherence to lipid-lowering therapy. Poor persistence may, in part, explain lower rates of achieving ATPIII lipid goals seen among women and racial/ethnic minorities.
PCV80 PERSISTENCE AND ADHERENCE TO HYPOLIPEMIC THERAPY IN REAL PRACTICE: RESULTS OF A LARGE ADMINISTRATIVE DATABASE
Mantovani LG 1 , Fornari C 2 , Madotto F 2 , Chiodini V 2 ,Veronesi G 3 , Ferrario M 3 , Cesana G 2 1 University of Naples, Federico II, Naples, Italy, 2 University of Milano-Bicocca, Monza, Lombardia, Italy, 3 University of Insubria, Varese, Lombardia, Italy OBJECTIVES: Chronic disease therapies have to be taken for long periods, usually indefinitely; hence the risk of discontinuation is often high. Low compliance/persistence may compromise the potential benefits of treatment. The purpose of this study was to investigate patients' adherence and persistence to therapy with hypolipemic medications using a large administrative database.
METHODS:
We used the Regione Lombardia Health Service (RLHS) administrative databases, which contain information on a population of >9 millions individuals with universal health care and pharmaceutical coverage. The study population included individuals with at least one prescription of a hypolipemic agent during the year 2003 and who were enrolled in the RLHS in the year 2003. Persistence and adherence was evaluated with the medication possession ratio (MPR), calculated as the ratio between the number of pills dispensed during the study period and the number of days of observation. MPR was estimated for individuals who filled their first prescription in the year before 31 October 2003. RESULTS: Out of a population of 9,108,645 members, 560,737 (6.2%) received at least one prescription of a study drug. Frequency of use increased from 0.7% in subjects with age <40 years to 18.4% in subjects age 70-79 y.o. A total of 16.2% of subjects received one or two packs during the study period, the median number of packs prescribed was 14, and
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